血液|還在用肌酐測腎功能?這個指標更準確,更有效!( 二 )


因此 , 在臨床上進行GcfDNA動態監測可以在血肌酐沒有明顯變化時(或者明顯升高時)早一步發現是否發生抗體介導的排斥反應 , 可避免移植腎的過早失功 。
參考資料:
1.Beck J, Bierau S, et al. Digital droplet PCR for rapid quantification of donor DNA in the circulation of transplant recipients as a potential universal biomarker of graft injury. Clin Chem 59: 1732–1741, 2013
2. De Vlaminck I, Valantine HA, et al. Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection. Sci Transl Med 6: 241ra77, 2014
3. Hidestrand M, Tomita-Mitchell A, et al. Highly sensitive noninvasive cardiac transplant rejection monitoring using targeted quantification of donor-specific cell-free deoxyribonucleic acid. J Am Coll Cardiol 63: 1224–1226, 2014
4. Grskovic M, Hiller DJ, et al. Validation of a clinicalgrade assay to measure donor-derived cell-free DNA in solid organ transplant recipients. J Mol Diagn 18:890–902, 2016
5. De Vlaminck I, Martin L, et al. Noninvasive monitoring of infection and rejection after lung transplantation. Proc Natl Acad Sci USA 112: 13336–13341, 2015
6. Schutz E, Blum A, et al. Graft-derived cell-free DNA - a promising rejection marker in liver transplantation - results from a prospective multicenter trial [Abstract]. Clin Chem 62: S41, 2016
7.Bloom R D, Bromberg J S, Poggio E D, et al. Cell-Free DNA and Active Rejection in Kidney Allografts. Journal of the American Society of Nephrology, 2017
血液|還在用肌酐測腎功能?這個指標更準確,更有效!
文章圖片